BridgeMD
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
EU CTIS ID: 2026-525817-29-00
What this study is testing
To assess safety and tolerability of SUN-627
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Aged 18-70, inclusive
- Diagnosis of PPMS or non-active SPMS
- No MS relapses in the past 2 years
- Evidence that MS has continued to get worse over time
- A level of disability that fits the study requirements
- Additional inclusion criteria are outlined in the full study protocol.
You likely can't join if
- Use of certain medications or treatments before the study, or need for these treatments during the study
- Current participation in another research study
- Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk
- Certain serious or unstable medical conditions that could make the study unsafe
- Active infection, recent infection, or a history of repeated infections
- Additional exclusion criteria are outlined in the full study protocol.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.